Relapse of minimal change disease nephrotic syndrome after administering intravitreal bevacizumab. | Nefrologia;34(3): 421-2, 2014 May 21. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

VHL Regional Portal

Information and Knowledge for Health

Subject descriptor lookup Advanced Search EVID@Easy

Relapse of minimal change disease nephrotic syndrome after administering intravitreal bevacizumab.

Pérez-Valdivia, Miguel A; López-Mendoza, Manuel; Toro-Prieto, Francisco J; Cabello-Chaves, Virginia; Toro-Ramos, Mercedes; Martín-Herrera, M Carmen; Gómez-García, Luis.

Nefrologia ; 34(3): 421-2, 2014 May 21.

Article in En, Es | MEDLINE | ID: mdl-24849064

Subject(s)

Antibodies, Monoclonal, Humanized/adverse effects; Nephrosis, Lipoid/chemically induced; Antibodies, Monoclonal, Humanized/administration & dosage; Bevacizumab; Humans; Intravitreal Injections; Male; Middle Aged; Recurrence

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antibodies, Monoclonal, Humanized / Nephrosis, Lipoid Limits: Humans / Male / Middle aged Language: En / Es Journal: Nefrologia Year: 2014 Document type: Article Country of publication: Spain

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antibodies, Monoclonal, Humanized / Nephrosis, Lipoid Limits: Humans / Male / Middle aged Language: En / Es Journal: Nefrologia Year: 2014 Document type: Article Country of publication: Spain